Pseudoprogression after radiation therapies for low grade glioma in children and adults: A systematic review and meta-analysis

被引:26
|
作者
Lu, Victor M. [1 ]
Welby, John P. [1 ]
Laack, Nadia N. [2 ]
Mahajan, Anita [2 ]
Daniels, David J. [1 ]
机构
[1] Mayo Clin, Dept Neurosurg, Rochester, MN USA
[2] Mayo Clin, Dept Radiat Oncol, Rochester, MN USA
关键词
Pseudoprogression; Low-grade glioma; Proton; Photon; Radiation; Pediatric; GLIOBLASTOMA-MULTIFORME PATIENTS; PROTON; EPIDEMIOLOGY; RADIOTHERAPY; TEMOZOLOMIDE; MANAGEMENT; RISK;
D O I
10.1016/j.radonc.2019.07.013
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Pseudoprogression (PsP) following radiation therapy (RT) for low grade glioma (LGG, WHO grade I and II), including both photon-based intensity-modulated RT (IMRT) and proton beam therapy (PBT), has been described. However, its incidence has yet to be consolidated. The aim of this systematic review and meta-analysis was to pool the current literature and establish the incidence of PsP in these groups to better inform surveillance protocols in the future. Methods: Searches of 4 electronic databases from inception to April 2019 were conducted following PRISMA guidelines. Articles were screened against pre-specified criteria. The incidence of outcomes was then extracted and pooled by random-effects meta-analysis of proportions. Results: A total of 5 pediatric and 4 adult cohort studies describing 517 and 424 LGG subjects respectively satisfied all selection criteria. The estimated incidences of PsP in pediatric subjects following IMRT and PBT were 33% (95% CI, 20-47%) and 34% (95% CI, 23-45%) respectively, with no difference between modalities. The estimated incidences of PsP in adult subjects following IMRT and PBT were 18% (95% CI, 12-25%) and 30% (95% CI, 21-39%) respectively, with PsP significantly less common following IMRT than PBT (P-heterogeneity = 0.04). Median time from radiation initiation to first detection of PsP ranged from 6 to 12 months across all modalities and age groups. Conclusions: The incidence of PsP following both IMRT and PBT in the management of pediatric and adult LGG is not negligible, and should therefore be recognized as a pertinent sequala within the first year at least following treatment. However, a lack of accountability in the current literature for the differences in PsP interpretation, radiation modality, radiobiology and molecular biology of LGGs precludes any firm surveillance recommendations at this time. (C) 2019 Elsevier B.V. All rights reserved.
引用
收藏
页码:36 / 42
页数:7
相关论文
共 50 条
  • [1] MANAGEMENT OF LOW-GRADE GLIOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Brown, T. J.
    Bota, D.
    Maher, E.
    Aregawi, D.
    Liau, L. M.
    Buckner, J.
    Weller, M.
    van den Bent, M. J.
    Berger, M. S.
    Glantz, M.
    NEURO-ONCOLOGY, 2017, 19 : 85 - 85
  • [2] Management of low-grade glioma: a systematic review and meta-analysis
    Brown, Timothy J.
    Bota, Daniela A.
    van den Bent, Martin J.
    Brown, Paul D.
    Maher, Elizabeth
    Aregawi, Dawit
    Liau, Linda M.
    Buckner, Jan C.
    Weller, Michael
    Berger, Mitchel S.
    Glantz, Michael
    NEURO-ONCOLOGY PRACTICE, 2019, 6 (04) : 249 - 258
  • [3] Pseudoprogression in Pediatric Low-Grade Glioma After Radiation Therapy
    Tsang, D. S.
    Murphy, E. S.
    Lucas, J. T., Jr.
    Lagiou, P.
    Acharya, S.
    Merchant, T. E.
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S6 - S6
  • [4] Pseudoprogression After Irradiation in Pediatric Low Grade Glioma
    Tsang, D. S.
    Murphy, E. S.
    Lucas, J. T., Jr.
    Lagiou, P.
    Merchant, T. E.
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S134 - S135
  • [5] Quantifying the benefit of chemotherapy and radiation in low-grade glioma: A systematic review and meta-analysis of numbers needed to treat.
    Brown, Timothy J.
    Bota, Daniela Annenelie
    Maher, Elizabeth A.
    Aregawi, Dawit Gebremichael
    Liau, Linda M.
    Brown, Paul D.
    Buckner, Jan C.
    Weller, Michael
    Van den Bent, Martin J.
    Berger, Mitchel S.
    Glantz, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] Incidence of Tumour Progression and Pseudoprogression in High-Grade Gliomas: a Systematic Review and Meta-Analysis
    Abdul W. Abbasi
    Henriette E. Westerlaan
    Gea A. Holtman
    Kamal M. Aden
    Peter Jan van Laar
    Anouk van der Hoorn
    Clinical Neuroradiology, 2018, 28 : 401 - 411
  • [7] Discriminators of pseudoprogression and true progression in high-grade gliomas: A systematic review and meta-analysis
    Chris Taylor
    Justyna O. Ekert
    Viktoria Sefcikova
    Naomi Fersht
    George Samandouras
    Scientific Reports, 12
  • [8] Incidence of Tumour Progression and Pseudoprogression in High-Grade Gliomas: a Systematic Review and Meta-Analysis
    Abbasi, Abdul W.
    Westerlaan, Henriette E.
    Holtman, Gea A.
    Aden, Kamal M.
    van Laar, Peter Jan
    van der Hoorn, Anouk
    CLINICAL NEURORADIOLOGY, 2018, 28 (03) : 401 - 411
  • [9] Discriminators of pseudoprogression and true progression in high-grade gliomas: A systematic review and meta-analysis
    Taylor, Chris
    Ekert, Justyna O.
    Sefcikova, Viktoria
    Fersht, Naomi
    Samandouras, George
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [10] Chemotherapy for Adults with Malignant Glioma: A Systematic Review and Network Meta-Analysis
    Wang, Wen
    Shi, Guang
    Ma, Binbin
    Ha, Xiangcheng
    Dong, Xin
    Zhang, Bo
    TURKISH NEUROSURGERY, 2017, 27 (02) : 174 - 181